Economic evaluations of rotavirus immunization for developing countries: A review of the literature

Expert Review of Vaccines

Volumn 10, Issue 7, 2011, Pages 1037-1051

  Tu, Hong Anh T ^a   Woerdenbag, Herman J ^a   Kane, Sumit ^b   Rozenbaum, Mark H ^a   Li, Shu Chuen ^c   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b ROYAL TROPICAL INSTITUTE   (Netherlands)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

cost effectiveness; developing country; rotavirus vaccination

Indexed keywords

ROTAVIRUS VACCINE;

AFRICA; ASIA; CHILDHOOD MORTALITY; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DIARRHEA; DRUG EFFICACY; ECONOMIC EVALUATION; FINANCIAL MANAGEMENT; HUMAN; IMMUNIZATION; PRIORITY JOURNAL; REVIEW; ROTAVIRUS; WORLD HEALTH ORGANIZATION;

CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DIARRHEA; HUMANS; INFANT; INFANT, NEWBORN; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 80051482752     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.65     Document Type: Review

References (35)

1. Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull. World Health Organ. 81(3), 197-204 (2003). (Pubitemid 36372958)
2. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg. Infect. Dis. 9(5), 565-572 (2003). (Pubitemid 36529515)
3. Santosham M, Chandran A, Fitzwater S, Fischer-Walker C, Baqui AH, Black R. Progress and barriers for the control of diarrhoeal disease. Lancet 376 (9734), 63-67 (2010).
4. Parashar UD, Burton A, Lanata C et al. Global mortality associated with rotavirus disease among children in 2004. J. Infect. Dis. 200(Suppl. 1), S9-S15 (2009).
5. World Health Organization. WHO. Global networks for surveillance of rotavirus gastroenteritis, 2001-2008. Wkly Epidemiol. Rec. 83(47), 421-428 (2008).
6. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR et al. Safety and effcacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med. 354(1), 11-22 (2006). (Pubitemid 43048947)
7. Vesikari T, Matson DO, Dennehy P et al. Safety and effcacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 354(1), 23-33 (2006). (Pubitemid 43048948)
8. Vesikari T, Karvonen A, Prymula R et al. Effcacy of human rotavirus vaccine against rotavirus gastroenteritis during the frst 2 years of life in European infants: randomised, double-blind controlled study. Lancet 370(9601), 1757-1763 (2007). (Pubitemid 350137490)
9. Armah GE, Sow SO, Breiman RF et al. Effcacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 376(9741), 606-614 (2010).
10. Madhi SA, Cunliffe NA, Steele D et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N. Engl. J. Med. 362(4), 289-298 (2010).
11. Zaman K, Dang DA, Victor JC et al. Effcacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 376(9741), 615-623 (2010).
12. Expanded Programme on Immunization of the Department of Immunization, Vaccines and Biologicals. Introduction of rotavirus vaccines into national immunization programmes. World Health Organization, Geneva, Switzerland (2009).
13. Berry SA, Johns B, Shih C, Berry AA, Walker DG. The cost-effectiveness of rotavirus vaccination in Malawi. J. Infect. Dis. 202(Suppl), S108-S115 (2010).
14. Wilopo SA, Kilgore P, Kosen S et al. Economic evaluation of a routine rotavirus vaccination programme in Indonesia. Vaccine 27(Suppl. 5), F67-F74 (2009).
15. World Bank. World Development Report 1993: Investing in Health. New York: The World Bank, 1993. Oxford University Press, Washington DC, DC, USA (2010).
16. Fischer TK, Anh DD, Antil L et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J. Infect. Dis. 192(10), 1720-1726 (2005). (Pubitemid 41587821)
17. Flem ET, Latipov R, Nurmatov ZS, Xue Y, Kasymbekova KT, Rheingans RD. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in Kyrgyzstan. J. Infect. Dis. 200(Suppl. 1), S195-S202 (2009).
18. Isakbaeva ET, Musabaev E, Antil L et al. Rotavirus disease in Uzbekistan: Cost-effectiveness of a new vaccine. Vaccine 25(2), 373-380 (2007). (Pubitemid 44856079)
19. Kim SY, Goldie SJ, Salomon JA. Cost-effectiveness of rotavirus vaccination in Vietnam. BMC Public Health 9, 29 (2009).
20. Rose J, Hawthorn RL, Watts B, Singer ME. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ 339, b3653-b3665 (2009).
21. Wang XY, Riewpaiboon A, von Seidlein L et al. Potential cost-effectiveness of a rotavirus immunization program in rural China. Clin. Infect. Dis. 49(8), 1202-1210 (2009).
22. Ortega O, El-Sayed N, Sanders JW et al Cost-beneft analysis of a rotavirus immunization program in the Arab Republic of Egypt. J. Infect. Dis. 200(Suppl. 1), S92-S98 (2009).
23. Tate JE, Rheingans RD, O'Reilly CE et al. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in kenya. J. Infect. Dis. 200(Suppl. 1), S76-S84 (2009).
24. Constenla DO, Linhares AC, Rheingans RD, Antil LR, Waldman EA, da Silva LJ. Economic impact of a rotavirus vaccine in Brazil. J. Health Popul. Nutr. 26(4), 388-396 (2008).
25. De la Hoz F, Alvis N, Narvaez J, Cediel N. Potential epidemiological and economic impact of two rotavirus vaccines in Colombia. Vaccine 28(22), 3856-3864 (2010).
26. de Soarez PC, Valentim J, Sartori AM, Novaes HM. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev. Panam. Salud Publica 23(4), 221-230 (2008).
27. Valencia-Mendoza A, Bertozzi SM, Gutierrez JP, Itzler R. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico. BMC Infect. Dis. 8, 103-116 (2008).
28. Chotivitayatarakorn P, Chotivitayatarakorn P, Poovorawan Y. Cost-effectiveness of rotavirus vaccination as part of the national immunization program for Thai children. Southeast Asian J. Trop.Med. Public Health 41(1), 114-125 (2010).
29. World Health Organization. Generic protocol for monitoring impact of rotavirus vaccination on gastroenteritis disease burden and viral strains. World Health Organization, Geneva, Switzerland (2009).
30. Naghipour M, Nakagomi T, Nakagomi O. Issues with reducing the rotavirus-associated mortality by vaccination in developing countries. Vaccine 26(26), 3236-3241 (2008).
31. Adam T, Baltussen R, Tan Torres T et al. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. World Health Organization, Geneva, Switzerland (2003).
32. Griffths U, Rheingans R, Walker D. Guidelines for Estimating the Economic Burden of Diarrhoeal Disease with Focus on Assessing the Costs of Rotavirus Diarrhea. World Health Organization, Geneva, Switzerland (2005).
33. World Health Organization. Rotavirus vacccination. Wkly Epidemiol. Rec. 84, 213-236 (2009).
34. Flem ET, Kasymbekova KT, Vainio K et al. Rotavirus infection in hospitalized children and estimates of disease burden in Kyrgyzstan, 2005-2007. Vaccine 27(Suppl. 5), F35-F39 (2009).
35. Atherly D, Dreibelbis R, Parashar UD, Levin C, Wecker J, Rheingans RD. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J. Infect. Dis. 200(Suppl. 1), S28-S38 (2009).